Hydrocodone/Acetaminophen 7.5mg/750mg | Hydrocodone Bitartrate and Acetaminophen

14:33 EDT 23rd October 2014 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Hydrocodone Bitartrate and Acetaminophen Tablets are supplied in tablet form for oral administration

CLINICAL PHARMACOLOGY

Hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain.

This product should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen.

Patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone.

WARNINGS

Respiratory Depression – At high doses or in sensitive patients, hydrocodone may produce dose-related respiratory depression by acting directly on the brain stem respiratory center. Hydrocodone also affects the center that controls respiratory rhythm, and may produce irregular and periodic breathing.

Head Injury and Increased Intracranial Pressure – The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

Acute Abdominal Conditions – The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

Drug/Laboratory Test Interactions – Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.

Carcinogenesis, Mutagenesis, Impairment of Fertility – No adequate studies have been conducted in animals to determine whether hydrocodone or acetaminophen have a potential for carcinogenesis, mutagenesis, or impairment of fertility.

Hydrocodone and the major metabolites of acetaminophen are known to be substantially excreted by the kidney. Thus the risk of toxic reactions may be greater in patients with impaired renal function due to the accumulation of the parent compound and/or metabolites in the plasma. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Hydrocodone may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of hydrocodone bitartrate and acetaminophen tablets and observed closely.

Dermatological – Skin rash, pruritus.

The following adverse drug events may be borne in mind as potential effects of acetaminophen: allergic reactions, rash, thrombocytopenia, agranulocytosis.

Potential effects of high dosage are listed in the OVERDOSAGE section.

Controlled Substance – Hydrocodone bitartrate and acetaminophen tablets are classified as a Schedule III controlled substance.

Abuse and Dependence – Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of narcotics; therefore, this product should be prescribed and administered with caution. However, psychic dependence is unlikely to develop when hydrocodone bitartrate and acetaminophen tablets are used for a short time for the treatment of pain.

Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued narcotic use, although some mild degree of physical dependence may develop after a few days of narcotic therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients.

OVERDOSAGE

Methemoglobinemia over 30% should be treated with methylene blue by slow intravenous administration.

The toxic dose of acetaminophen for adults is 10 grams.


Product Strength

Usual Adult Dosage as needed for pain

The total 24-hour dosage should not exceed
5 mg/325 mg One to two tablets every four to six hours 12 tablets
5 mg/500 mg One to two tablets every four to six hours 8 tablets
7.5 mg/325 mg One tablet every four to six hours 8 tablets
7.5 mg/500 mg One tablet every four to six hours 6 tablets
7.5 mg/650 mg One tablet every four to six hours 6 tablets
7.5 mg/750 mg One tablet every four to six hours 5 tablets
10 mg/325 mg One tablet every four to six hours 6 tablets
10 mg/500 mg One tablet every four to six hours 6 tablets
10 mg/650 mg One tablet every four to six hours 6 tablets
10 mg/660 mg One tablet every four to six hours 6 tablets
10 mg/750 mg One tablet every four to six hours 5 tablets

Hydrocodone Bitartrate and Acetaminophen Tablets USP are supplied as follows:

Dispense in a tight, light-resistant container (as defined in USP) with a child-resistant closure.

Storage – Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.

A Schedule III Narcotic.

Mallinckrodt Inc.Hazelwood, MO 63042 USA

COVIDIEN™ Mallinckrodt

Printed in U.S.A.

Rev 10/2009

Strength How Supplied Each tablet contains: Description of tablet
Hydrocodone Bitartrate Acetaminophen
5 mg/325 mg Bottles of 100 ……… NDC 0406-0365-01
Unit Dose (10 x 10) … NDC 0406-0365-62

5 mg 325 mg It is available as a capsule-shaped white tablet debossed with M365 on one side and bisected on the other side.
5 mg/500 mg Bottles of 90 ….……NDC 0406-0357-09
Bottles of 100 ….……NDC 0406-0357-01
Bottles of 500 …….…NDC 0406-0357-05
Unit Dose (10 x 10) .….NDC 0406-0357-62
5 mg 500 mg It is available as a capsule-shaped white tablet debossed with M357 on one side and bisected on the other side.
7.5 mg/325 mg Bottles of 100 …….…NDC 0406-0366-01
Unit Dose (10 x 10) ….NDC 0406-0366-62

7.5 mg 325 mg It is available as an unscored oval-shaped white tablet debossed with M366 on one side.
7.5 mg/500 mg Bottles of 100 …….…NDC 0406-0358-01
Bottles of 500 …….…NDC 0406-0358-05
Unit Dose (10 x 10) …..NDC 0406-0358-62
7.5 mg 500 mg It is available as a capsule-shaped white tablet debossed with M358 on one side and bisected on the other side.
7.5 mg/650 mg Bottles of 100 ……… NDC 0406-0359-01
Bottles of 500 ……… NDC 0406-0359-05

7.5 mg 650 mg It is available as a capsule-shaped white tablet debossed with M359 on one side and bisected on the other side.
7.5 mg/750 mg Bottles of 90 ….……NDC 0406-0360-09
Bottles of 100 ……… NDC 0406-0360-01
Bottles of 500 ……… NDC 0406-0360-05

7.5 mg 750 mg It is available as a capsule-shaped white tablet debossed with M360 on one side and bisected on the other side.
10 mg/325 mg Bottles of 100 …….… NDC 0406-0367-01
Bottles of 500 ….…… NDC 0406-0367-05
Unit Dose (10 x 10) ….. NDC 0406-0367-62
10 mg 325 mg It is available as a capsule-shaped white tablet debossed with M367 on one side and bisected on the other side.
10 mg/500 mg Bottles of 100 …….… NDC 0406-0363-01
Bottles of 500 ……… NDC 0406-0363-05
Unit Dose (10 x 10) …. NDC 0406-0363-62
10 mg 500 mg It is available as a capsule-shaped white tablet debossed with M363 on one side and bisected on the other side.
10 mg/650 mg Bottles of 100 ……..…NDC 0406-0361-01
Bottles of 500 …….… NDC 0406-0361-05
Unit Dose (10 x 10). ….NDC 0406-0361-62
10 mg 650 mg It is available as a capsule-shaped blue tablet debossed with M361 on one side and bisected on the other side.
10 mg/660 mg Bottles of 100 ………. NDC 0406-0362-01


10 mg 660 mg It is available as a capsule-shaped white tablet debossed with M362 on one side and bisected on the other side.
10 mg/750 mg Bottles of 100 ………. NDC 0406-0364-01


10 mg 750 mg It is available as a capsule-shaped white tablet debossed with M364 on one side and bisected on the other side.

Information for Patients – Hydrocodone, like all narcotics, may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery; patients should be cautioned accordingly.

Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.

Hydrocodone may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.

Laboratory Tests – In patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.

Drug Interactions – Patients receiving narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone bitartrate and acetaminophen tablets may exhibit an additive CNS depression. When combined therapy is contemplated, the dose of one or both agents should be reduced.

The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.

Drug/Laboratory Test Interactions – Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.

Carcinogenesis, Mutagenesis, Impairment of Fertility – No adequate studies have been conducted in animals to determine whether hydrocodone or acetaminophen have a potential for carcinogenesis, mutagenesis, or impairment of fertility.

Teratogenic Effects. Pregnancy Category C – There are no adequate and well-controlled studies in pregnant women. Hydrocodone bitartrate and acetaminophen tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects – Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal.

Nursing Mothers – Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. It is not known whether hydrocodone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use – Safety and effectiveness in pediatric patients have not been established.

Geriatric Use – Clinical studies of hydrocodone bitartrate and acetaminophen tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Hydrocodone and the major metabolites of acetaminophen are known to be substantially excreted by the kidney. Thus the risk of toxic reactions may be greater in patients with impaired renal function due to the accumulation of the parent compound and/or metabolites in the plasma. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Hydrocodone may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of hydrocodone bitartrate and acetaminophen tablets and observed closely.

Image of label

Manufacturer

Lake Erie Medical DBA Quality Care Products LLC

Active Ingredients

Source

Drugs and Medications [1607 Associated Drugs and Medications listed on BioPortfolio]

Trezix [WraSer LLC]

TREZIX™ Capsules

Hydrocodone bitartrate and homatropine methylbromide [Rebel Distributors Corp]

Hydrocodone Bitartrate and Homatropine Methylbromide Syrup

Hydrocodone bitartrate and homatropine methylbromide [Hi-Tech Pharmacal Co., Inc.]

Hydrocodone Bitartrate and Homatropine Methylbromide Syrup

Hydrocodone bitartrate and homatropine methylbromide [Novel Laboratories, Inc.]

Hydrocodone Bitartrate and Homatropine Methylbromide Tablets, USP

Hydrocodone bitartrate and homatropine methylbromide [GAVIS Pharmaceuticals, LLC]

Hydrocodone Bitartrate and Homatropine Methylbromide Tablets, USP

Clinical Trials [145 Associated Clinical Trials listed on BioPortfolio]

A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament

The purpose of this study is to explore the pain-relieving effects and safety of two analgesic treatment regimens as compared to placebo in patients experiencing acute musculoskeletal pain...

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction

The purpose of this study is to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen compared to placebo in moderate to severe pain following molar extraction.

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

This Phase 3, multi-center study will evaluate the long-term safety and tolerability of hydrocodone bitartrate controlled release capsule (HC-CR) at daily doses of 40 mg or more in subject...

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain.

A Study Comparing Vicodin® CR and NORCO® to Placebo in Subjects With Acute Pain Following Bunionectomy

The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of Extended Release Hydrocodone/Acetaminophen and Immediate Release Hydr...

PubMed Articles [123 Associated PubMed Articles listed on BioPortfolio]

NQO2 is a reactive oxygen species generating off-target for acetaminophen.

The analgesic and antipyretic compound acetaminophen (paracetamol) is one of the most used drugs worldwide. Acetaminophen overdose is also the most common cause for acute liver toxicity. Here we show ...

Analgesic interaction between ondansetron and acetaminophen after tonsillectomy in children: The Paratron randomized, controlled trial.

The mechanism of action of acetaminophen remains unclear. One hypothesis involves an interaction with the serotoninergic system. Antagonists to serotonin (5-HT)3 receptors (setrons) have antiemetic pr...

Drug Utilization, Dosing, and Costs After Implementation of Intravenous Acetaminophen Guidelines for Pediatric Patients.

The objectives of this evaluation of medication use were to characterize the use of intravenous acetaminophen at our institution and to determine if acetaminophen was prescribed at age-appropriate dos...

Association between Recent Acetaminophen Use and Asthma: Modification by Polymorphism at TLR4.

The risk of asthma has been increasing in parallel with use of acetaminophen, which is a potential source of oxidative stress. Toll-like receptor 4 (TLR4) plays a critical role not only in innate immu...

Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.

Infantile neuronal ceroid lipofuscinosis is a devastating neurodegenerative lysosomal storage disease caused by mutations in the gene (CLN1 or PPT1) encoding palmitoyl-protein thioesterase-1 (PPT1). W...

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Anesthesiology
Latest News Clinical Trials Research Drugs Reports Corporate
An anesthesiologist (US English) or anaesthetist (British English) is a physician trained in anesthesia and perioperative medicine. Anesthesiologists are physicians who provide medical care to patients in a wide variety of (usually acute) situations. ...

Psychiatry
Latest News Clinical Trials Research Drugs Reports Corporate
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Advertisement

Drugs and Medication Quicklinks


Searches Linking to this Drug Record